A viral Instagram post in October 2026 called histotripsy a sound-wave breakthrough that destroys cancer without surgery. Strategically, that framing runs ahead of the evidence. What the regulator cleared is narrower, and the trial numbers are mixed.
What the FDA actually cleared
On October 9, 2023, HistoSonics announced that the FDA had granted marketing authorization to its Edison System through the De Novo Classification Request process, a review route for devices with no existing predicate. That made Edison the first and only histotripsy platform available in the United States.
The indication is specific: non-invasive destruction of liver tumors, including unresectable ones, using a non-thermal, mechanical process of focused ultrasound. The FDA has not evaluated the system for the treatment of cancer, or for any cancer outcome such as local tumor progression, 5-year survival or overall survival. Its use is limited to people trained by HistoSonics.
The method itself came out of the University of Michigan, where the work began in 2001. Focused sound energy produces controlled acoustic cavitation, bubbles that grow and collapse and liquefy the targeted tissue at a sub-cellular level. The body then absorbs what is left. Mike Blue, the company’s president and CEO, called the clearance “most meaningful milestone to date”.
The HOPE4LIVER numbers
Authorization rested partly on pooled data from the US and European HOPE4LIVER trials. Forty-four subjects were evaluated for safety and 44 treated tumors for efficacy. Eighteen subjects had hepatocellular carcinoma; 26 had liver metastases from the colon, rectum, breast and other primary sites. Technical success reached 95.5%, a figure presented at the CIRSE Congress in Copenhagen, meaning physicians could precisely target and destroy the intended tissue.
Safety looked acceptable. Three procedure-related events of CTCAE Grade 3 or higher turned up through 30 days across all 44 subjects, a complication rate of 6.8%. A Radiology paper from 2024 reported the same trials meeting both co-primary goals, with technical success in 42 of 44 tumors.
The one-year follow-up is where the picture gets less tidy. Published in 2025 in the Annals of Surgery, it covered 47 patients at 14 sites in the United States and Europe, all ineligible for standard therapies or having opted out. Nineteen had hepatocellular carcinoma and 28 had metastatic disease. Fifty-two tumors were treated.
The 1-year local control rate was 63.4% by the primary assessment method. A post hoc assessment, done to allow for a learning curve in reading images of a new therapy, put it at 90%. Overall survival at one year was 73.3% for hepatocellular carcinoma and 48.6% for metastatic disease. There were 6 serious adverse device-related effects within 30 days, and only one nonserious device-related effect after that.
The authors concluded that local control is consistent with current locoregional therapies and that survival is comparable for similar disease stages. That is a respectable result. It is not a cure.
Where the research goes next
HistoSonics says it is working to extend histotripsy to other organs, including the kidney and pancreas. Michigan has meanwhile opened a $10 million Histotripsy Center in the College of Engineering. Zhen Xu, a biomedical engineering professor and co-inventor of histotripsy, told The Daily its main purpose is research, not patient care, and that researchers from other universities can use it free of charge.
Anyone with a liver tumor should ask their doctor or oncologist whether this therapy fits their case.
Sources
- The #HOPE4LIVER Single-arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors
- The #HOPE4LIVER Single-Arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors.
- FDA Awards HistoSonics Clearance of its First-of-a-Kind Edison® Histotripsy System – HistoSonics
- UMich launches world’s first histotripsy center, advancing non-invasive cancer treatment research – The Michigan Daily
Photo: Harrison Keely (CC BY 4.0)
